233 related articles for article (PubMed ID: 33721122)
1. Liver-Directed Therapies for Neuroendocrine Neoplasms.
Clift AK; Frilling A
Curr Oncol Rep; 2021 Mar; 23(4):44. PubMed ID: 33721122
[TBL] [Abstract][Full Text] [Related]
2. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
Braat AJAT; Bruijnen RCG; van Rooij R; Braat MNGJA; Wessels FJ; van Leeuwaarde RS; van Treijen MJC; de Herder WW; Hofland J; Tesselaar MET; de Jong HWAM; Lam MGEH
Lancet Oncol; 2020 Apr; 21(4):561-570. PubMed ID: 32112737
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature.
Bester L; Meteling B; Boshell D; Chua TC; Morris DL
J Med Imaging Radiat Oncol; 2014; 58(3):341-52. PubMed ID: 24589204
[TBL] [Abstract][Full Text] [Related]
4. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
[TBL] [Abstract][Full Text] [Related]
5. Transarterial liver-directed therapies of neuroendocrine hepatic metastases.
Nazario J; Gupta S
Semin Oncol; 2010 Apr; 37(2):118-26. PubMed ID: 20494704
[TBL] [Abstract][Full Text] [Related]
6. [Radiologically guided interventional therapies for the treatment of neuroendocrine tumors].
Radosa CG; Nebelung H; Schön F; Hoffmann RT
Radiologie (Heidelb); 2024 Jul; 64(7):575-581. PubMed ID: 38761204
[TBL] [Abstract][Full Text] [Related]
7. Liver transarterial embolizations in metastatic neuroendocrine tumors.
de Mestier L; Zappa M; Hentic O; Vilgrain V; Ruszniewski P
Rev Endocr Metab Disord; 2017 Dec; 18(4):459-471. PubMed ID: 28975561
[TBL] [Abstract][Full Text] [Related]
8. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
[TBL] [Abstract][Full Text] [Related]
9. The Landmark Series: Neuroendocrine Tumor Liver Metastases.
Gangi A; Howe JR
Ann Surg Oncol; 2020 Sep; 27(9):3270-3280. PubMed ID: 32632880
[TBL] [Abstract][Full Text] [Related]
10. Management of patients with hepatic metastases from neuroendocrine tumors.
Clift AK; Frilling A
Ann Saudi Med; 2014; 34(4):279-90. PubMed ID: 25811199
[TBL] [Abstract][Full Text] [Related]
11. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.
Grozinsky-Glasberg S; Kaltsas G; Kaltsatou M; Lev-Cohain N; Klimov A; Vergadis V; Uri I; Bloom AI; Gross DJ
Endocrine; 2018 Jun; 60(3):499-509. PubMed ID: 29383678
[TBL] [Abstract][Full Text] [Related]
12. Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy.
Rabei R; Fidelman N
Curr Treat Options Oncol; 2023 Dec; 24(12):1994-2004. PubMed ID: 38100020
[TBL] [Abstract][Full Text] [Related]
13. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost.
Whitney R; Vàlek V; Fages JF; Garcia A; Narayanan G; Tatum C; Hahl M; Martin RC
Oncologist; 2011; 16(5):594-601. PubMed ID: 21508068
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman OM; Elsayed Z
Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
[TBL] [Abstract][Full Text] [Related]
17. Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization).
Hoffmann RT; Paprottka P; Jakobs TF; Trumm CG; Reiser MF
Abdom Imaging; 2011 Dec; 36(6):671-6. PubMed ID: 21584635
[TBL] [Abstract][Full Text] [Related]
18. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.
Fiore F; Del Prete M; Franco R; Marotta V; Ramundo V; Marciello F; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A
Endocrine; 2014 Sep; 47(1):177-82. PubMed ID: 24385266
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic strategies for neuroendocrine liver metastases.
Frilling A; Clift AK
Cancer; 2015 Apr; 121(8):1172-86. PubMed ID: 25274401
[TBL] [Abstract][Full Text] [Related]
20. Radioembolization in the treatment of neuroendocrine tumors of the pancreas.
John PK; Saif MW
JOP; 2014 Jul; 15(4):332-4. PubMed ID: 25076336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
